HODGKIN LYMPHOMA (ADULT)

Size: px
Start display at page:

Download "HODGKIN LYMPHOMA (ADULT)"

Transcription

1 HODGKIN LYMPHOMA (ADULT) Executive Summary Hodgkin lymphoma (HL) is a lymphoid malignancy of B-cell origin which is classified into either nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) or classical Hodgkin lymphoma (chl) in accordance with 2008 WHO classification. This disease is more frequently a disease of young people between the ages of Although they have characteristics in common, these two disease entities differ in their clinical features and behavior as well as their cellular properties. chl accounts for 95% of all HLs and can be further subdivided into four histological subtypes: lymphocyte-rich (LR), nodular sclerosis (NS), mixed cellularity (MC) or lymphocyte-depleted (LD). 1 HL is an uncommon neoplasm with estimated number of cases of 65,950 cases globally, an incidence that varies significantly by age, sex, ethnicity, geographic location and socioeconomic status. 2 Incidence rates are higher in more developed regions and among males and lower in Asia. 3 However, HL accounts for 15% of all cancers in young adults globally with a high impact on quality of life. 3 Up to the 1960s, the 5-year survival rate for HL was less than 10% worldwide. 4 Since then, the outcome for patients diagnosed with HL has progressively improved, and the current 5-year OS rate increased up to 80% for patients with advanced and to more than 90% for those with limited stage disease. 5 A success attributed to improved chemotherapy and radiation therapy (RT) approach used to treat these patients. Among the regimens developed to treat HL, the regimen including doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine, referred to as ABVD is recommended as the standard therapy, and BEACOPP regimen (drugs listed on page 3) as an acceptable alternative for high-risk patients. Hence, we recommend that the drugs in ABVD and BEACOPP be included on the Essential Medicines List. Public Health Relevance GLOBOCAN estimates that in 2012 there were 65,950 cases and 25,469 deaths of Hodgkin s lymphoma worldwide. 32 Of these cases, 28,852 occurred in more developed regions and 37,098 occurred in less developed regions. The age-standardized rate of Hodgkin s lymphoma is 2.1 per 100,000 in more developed regions versus 0.6 in less developed regions. Regions most affected by Hodgkin s lymphoma include the Americas (ASR of 1.5 per 100,000), East Mediterranean Region (ASR of 1.5 per 100,000), and Europe (ASR of 2.0 per 100,000). The East Mediterranean region has the highest age-standardized mortality rate of 1.0 per 100,000. Men (ASR of 1.1 per 100,000) are slightly more at risk than women (ASR of 0.7 per 100,000) of developing Hodgkin s lymphoma. Hodgkin s lymphoma is most often diagnosed between ages of 15 and 30 and in populations older than Previous exposure to an Epstein-Barr viral infection is a possible risk factor for Hodgkin s lymphoma. Additionally, those infected with immune-compromising conditions, such as HIV/AIDS, are more at risk for developing Hodgkin s lymphoma. 33 1

2 Requirements for diagnosis, treatment, and monitoring Diagnostics: Pathology laboratory analysis of surgically excised lymph node, lymph node core or extranodal tissue is required. In classical Hodgkin lymphoma chl, the presence of Hodgkin and Reed Sternberg (HRS) cells is disease-defining while the detection of lymphocyte predominant (LP) cells is required for the diagnosis of NLPHL. The immunophenotype of the malignant cells in chl and NLPHL differs significantly. In contrast to HRS cells that stain consistently positive for CD30 and CD15, occasionally positive for CD20 and negative for CD45, LP cells are characterized by the expression of CD20 and CD45 but they lack CD15 and CD30. 1 Testing: It has been recommended that pre-treatment tests include staging utilizing contrast enhanced computed tomography (CT) scan, and blood counts and chemistries to assess critical organ function, including renal and hepatic function, and determine prognosis. Several groups have developed scoring systems to predict survival of patients and guide decision of therapy. Most consider the presence of constitutional symptoms, and bulky mediastinal disease, as unfavorable features in limited stage disease (stage I/II), whereas stage III/IV disease is considered advanced stage disease. 1 In addition, a baseline positron emission tomography (PET) should be carried out according to the recommendations for staging and response assessment in lymphoma whenever this diagnostic tool is available. 6,7 The PET/CT scan can be performed after two cycles of ABVD and complete response is associated with better prognosis and can result in a patient receiving overall fewer cycles of ABVD. If a PET-CT is performed; bone marrow biopsy is no longer indicated for HL. 6 To identify patients at increased risk for acute and/or long-term complications, pulmonary function tests should be performed in older patients.. Since chemotherapy and RT can potentially cause permanent fertility damage, reproductive counseling must be offered to young patients of both genders before treatment. 8 Administration and Care of Patients: Administration requires intravenous infusion capacity, and requires that the patient have regular access to clinical care. A central venous catheter such as a Hickman or PICC aids in minimizing pain that is associated with peripheral administration of ABVD. In developed countries administration is usually performed in outpatient facilities, though in other setting, patients may be treated in in-patient facilities. IV hydration and anti-emetics should accompany administration of ABVD. Careful monitoring is mandatory to prevent soft tissue extravasation, which can cause severe local reactions and necrosis, especially with dacarbazine. Monitoring requires that clinicians have access to laboratory facilities, as well as the ability to recognize and address potential adverse events caused by the treatment itself, including bone marrow suppression, infection, mucositis, nausea and vomiting. 9 Special attention is needed to acute reactions to bleomycin, including fever, and anaphylactoid reactions. 9 Bleomycin induced pulmonary toxicity (BPT), may occur in 20-30% of patients; while on therapy or up to 6 months after treatment. Patients receiving bleomycin should be assessed carefully for signs and 2

3 symptoms of pulmonary toxicity before each dose. A history of new or worsening dyspnoea or pulmonary crackles should lead to stopping of bleomycin until an alternative cause is identified. 8 Among patients, who develop BPT, omission of bleomycin does not compromise efficacy of therapy, but BPT diagnosis by itself could potentially compromise outcome. 10 Clinicians should be sensitive to aspects of fatigue and related (emotional) symptoms in patients and encourage their patients to seek further support if needed. 11 Overview of Regimens The treatment of HL (both chl & NLPHL) relies on multimodality treatment with standard chemotherapy, radiation therapy, and autologous or allogeneic stem cell transplantation in cases of relapsed disease (20-30% of advanced cases) 12. ABVD is considered the standard of care for HL in many countries. However, over the past decade, other regimens were developed for patients with advanced HL (stage III/IV) to improve efficacy or reduce toxicity. 12 Dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone (escalated BEACOPP or BEACOPP), was developed by the German Hodgkin Study Group (GHSG) to improve efficacy, and has emerged as a very effective regimen. Another combined modality therapy (CMT) approach is Stanford V. The premise of this protocol was to substantially lower the cumulative doses of agents known to contribute to late effects and modify RT for the same reason.the following tables include administration and dosing for ABVD, BEACOPP, and Stanford V, but exclude ancillary medications pertaining to the management of side effects. Standard Regimen (ABVD) 13 ABVD: 2-4 cycles for limited disease and 6-8 for advanced disease, (repeated every 28 days) Doxorubicin Intravenous infusion 25 mg/m 2 day 1&15 Bleomycin Intravenous infusion 10units/m 2 day 1&15 Vinblastine Intravenous infusion 6 mg/m 2 day 1&15 Dacarbazine Intravenous infusion 375 mg/m 2 day 1&15 Alternative Regimen BEACOPP: 6-8 cycles (repeated every 21 days) 14 Bleomycin Intravenous infusion 10 mg/m 2 day 8 Etoposide Intravenous infusion 200 mg/m 2 days 1-3 Doxoxrubicin Intravenous infusion 35 mg/m 2 day1 Cyclophosphamide Intravenous infusion 1250 mg/m 2 day1 Vincristine Intravenous infusion 1.4 mg/m 2 (maximum 2mg) day 8 Procarbazine Oral 100mg/m 2 days 1-7 Prednisone Oral 40 mg/m 2 days 1-14 GCSF* SQ starting day8 3

4 *Please refer to the supplemental document on granulocyte colony-stimulating factors that is appended to the overall proposal for details on the use of G-CSF. Review of Benefits and Harms Benefits CMT has transformed HL from a disease uniformly fatal few decades earlier to mostly a curable disease nowadays. The study by Canellos and colleagues established ABVD as more efficient and less toxic regimen as compared to other combinations. 13 In 1992, the Cancer and Leukemia Group B (CALGB) reported the results of a prospective three-group randomized trial involving 359 patients with Hodgkin's lymphoma. This trial compared the following regimens: ABVD for 6 to 8 months, Mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) for 6 to 8 months, and MOPP alternating with ABVD for 12 months. The trial was limited to patients with advanced disease (clinical stages III and IV). No radiotherapy was administered. The results indicated an event-free survival advantage of ABVD over MOPP but no differences in OS between the ABVD and MOPP groups. However, the toxicity profile was remarkably better with ABVD. These findings were confirmed in a follow-up study of the data published in 2002, and later at a median follow up of 20 years. 16 Most patients (more than 90-95%) with limited-stage disease, usually defined as nonbulky (largest tumor diameter < 10 cm) stage IA or IIA disease can be cured with 2-4 cycles of ABVD followed by involved field radiation therapy. 17 An alternative to ABVD as the standard of care for patients with advanced Hodgkin's lymphoma is the intensive regimen BEACOPP. This regimen has shown superior activity to ABVD in terms of improving event free survival in many randomized studies, but limited impact on OS. 18 However, it is associated with significant short-term and long-term toxic effects. As for Stanford V, randomized trials have failed to demonstrate superior outcome as compared to ABVD. 19,20 Harms and Toxicity Considerations Common Patients receiving chemotherapy for HL will suffer from temporary alopecia, and myelosuppression, including suppression of the neutrophil count increasing the risk of infection, although infection incidence remains low at 2%. 31 However, the escalated BEACOPP regimens, when compared to ABVD, caused more haematological toxicities and infections, with subsequently higher risk for transplant related mortality especially among those with poor performance status and patients older than 50 years. 21,22 Serious Patients should be monitored for symptoms indicating the existence of long-term toxicity, particularly of heart and lung. Treatment with bleomycin may result in late bleomycin-related pulmonary toxicity, particularly when used in combination with mediastinal irradiation. Toxicity 10,13,23, 31 may occur in up to 20-30% of patients and fatal pulmonary complications have occurred. There may be a significant decline in median forced vital capacity and diffusing capacity 4

5 (DLCO) 24. Therefore, a high index of suspicion is warranted to allow omission of the bleomycin as early as possible when toxicity occurs. Doxorubicin can lead to long term cardiomyopathy when cumulative doses exceed 450mg/m 2. However, ABVD provides cumulative doxorubicin doses of mg/m 2 and therefore is uncommonly associated with cardiomyopathy. Escalated BEACOPP regimens are associated with higher risk for gonadal toxicity especially among women. 26,27 Additionally, the BEACOPP regimen can lead to secondary malignancy in 2-7% of patients, cancer screening should be conducted regularly due to the increased risk. 22 Systematic Reviews The majority of patients with Hodgkin lymphoma are cured with ABVD. However, almost 20 % of patients with advanced disease fail to achieve complete remission. While several randomized trials have confirmed prolongation of progression-free survival with BEACOPP compared to ABVD, a survival advantage has been difficult to demonstrate. Given the comparable survival between BEACOPP and ABVD, as well as the greater toxicities of the former, including infertility, myelosuppression, and secondary malignancies the latter increased at least in one trial 28, we recommend ABVD to be added to the Essential Medicines List. A review of the 12 consecutive series of prospective, randomized therapeutic trials involving a total of 6200 patients with advanced Hodgkin's lymphoma, revealed only one trial in which a small statistically significant difference in overall survival was noted. 18 A meta-analysis of 5 randomized trials examining the efficacy of BEACOPP compared to ABVD for first line treatment of HL demonstrated the positive impact of BEACOPP on EFS but not OS. 22 A network meta-analysis of randomized trials comparing BEACOPP regimens to ABVD based regimens, demonstrated 10% OS advantage at 5 years, but emphasized the importance of availability of appropriate supportive care. 21 However, that difference was corrected by effective salvage therapy. 18 ESMO clinical practice guidelines endorse ABVD as standard regimen for patients with all stages, especially so for fit patients older than 60 years. For advanced stages, if BEACOPP is used, they emphasize the need for appropriate supportive care and close surveillance to control short and long term toxicities. 1 A similar recommendation was made by the British Committee for Standards in Haematology, the Italian Society of Haematology and the Italian Society of Experimental Haematology, and the Spanish Society of Haematology. 8,29,30 5

6 Recommendations The reviewers recommend the incorporation of Hodgkin Lymphoma treatment options into the WHO Model List of Essential Medicines, and recommend specifically that G-CSF be added to the core Essential Medicines List. Additions proposed for Section 8.2 of the EML G-CSF* *Please refer to the supplemental document on granulocyte colony-stimulating factors that is appended to the overall proposal for details on the use of G-CSF 6

7 References 1 Eichenauer, D. A. et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 25 Suppl 3, iii70-iii75 (2014). 2 GLOBOCAN. Estimated cancer incidence, mortality, and prevalence worldwide in Salati, M., Cesaretti, M., Macchia, M., Mistiri, M. E. & Federico, M. Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin. Mediterranean journal of hematology and infectious diseases 6, e , doi: /mjhid (2014). 4 Devita, V. T., Jr., Serpick, A. A. & Carbone, P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Annals of internal medicine 73, (1970). 5 Marcos-Gragera, R. et al. Survival of European patients diagnosed with lymphoid neoplasms in : results of the HAEMACARE project. Haematologica 96, , doi: /haematol (2011). 6 Cheson, B. D. et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol (2014). 7 Barrington, S. F. & Mikhaeel, N. G. When should FDG-PET be used in the modern management of lymphoma? British journal of haematology 164, Follows, G. A. et al. Guidelines for the first line management of classical Hodgkin lymphoma. British journal of haematology 166, 34-49, doi: /bjh (2014). 9 Hudson, M. M. et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 11, (1993). 10 Martin, W. G. et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 23, , doi: /jco (2005). 11 Calaminus, G. et al. Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 22, , doi: /s y (2014). 12 Advani, R. Optimal therapy of advanced Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2011, , doi: /asheducation (2011). 13 Canellos, G. P. et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. The New England journal of medicine 327, , doi: /nejm (1992). 14 Dann, E. J. et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109, , doi: /blood (2007). 15 Bartlett, N. L., Rosenberg, S. A., Hoppe, R. T., Hancock, S. L. & Horning, S. J. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 13, (1995). 7

8 16 Canellos, G. P., Niedzwiecki, D. & Johnson, J. L. Long-term follow-up of survival in Hodgkin's lymphoma. The New England journal of medicine 361, , doi: /nejmc (2009). 17 Bonadonna, G. et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22, , doi: /jco (2004). 18 Diehl, V. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. The New England journal of medicine 348, (2003). 19 Gobbi, P. G. et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23, , doi: /jco (2005). 20 Gordon, L. I. et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31, , doi: /jco (2013). 21 Skoetz, N. et al. Effect of initial treatment strategy on survival of patients with advancedstage Hodgkin's lymphoma: a systematic review and network meta-analysis. The Lancet 14, Bauer, K., Skoetz, N., Monsef, I., Engert, A. & Brillant, C. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. The Cochrane database of systematic reviews, CD007941, doi: / cd pub2 (2011). 23 Carde, P. et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11, (1993). 24 Hirsch, A. et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14, (1996). 25 Swerdlow, A. J. et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. Journal of the National Cancer Institute 99, , doi: /jnci/djk029 (2007). 26 Viviani, S. et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. European journal of cancer & clinical oncology 21, (1985). 27 Behringer, K. et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31, , doi: /jco (2013). 28 Josting, A. et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21, , doi: /jco (2003). 29 Brusamolino, E. et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian 8

9 Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 94, , doi: /haematol (2009). 30 Quero Blanco, C. et al. SEOM clinical guidelines for the treatment of Hodgkin's lymphoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 12, (2010). 31 Horwitz S, Yahalom J. Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide, Accessed 5 November Mayo Clinic: Hodgkin s Lymphoma Accessed 5 November

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line

More information

Solid tumors in patients treated for Hodgkin s disease: a report from the German Hodgkin Lymphoma Study Group

Solid tumors in patients treated for Hodgkin s disease: a report from the German Hodgkin Lymphoma Study Group Original article Annals of Oncology 15: 1079 1085, 2004 DOI: 10.1093/annonc/mdh273 Solid tumors in patients treated for Hodgkin s disease: a report from the German Hodgkin Lymphoma Study Group K. Behringer

More information

PET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto

PET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto PET/CT in Lymphoma Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto Outline 1. Introduction: PET/CT, how does it work? 2.Current

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Treatment of low-grade non-hodgkin lymphoma

Treatment of low-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade

More information

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

More information

DIFFUSE LARGE B-CELL LYMPHOMA

DIFFUSE LARGE B-CELL LYMPHOMA DIFFUSE LARGE B-CELL LYMPHOMA Executive Summary Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), constituting up to 40% of all cases globally.[1] This subtype

More information

Lymphomas after organ transplantation

Lymphomas after organ transplantation Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative

More information

Guidelines for the Management of Follicular Lymphoma

Guidelines for the Management of Follicular Lymphoma Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World

More information

Interesting Case Series. Periorbital Richter Syndrome

Interesting Case Series. Periorbital Richter Syndrome Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,

More information

The Lymphoma Guide Information for Patients and Caregivers

The Lymphoma Guide Information for Patients and Caregivers The Lymphoma Guide Information for Patients and Caregivers Ashton, lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引 前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金

More information

Because non-hodgkin's lymphoma is a more frequent and distinct disease I will discuss it in more details in this site study.

Because non-hodgkin's lymphoma is a more frequent and distinct disease I will discuss it in more details in this site study. Southern New Hampshire Medical Center Site report 2009 Lymphomas. Roger Hakimian, MD Foundation Hematology/Oncology 10 Prospect Street, Suite 202 Introduction Lymphomas are group of heterogeneous malignancy

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the

More information

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA 2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate

More information

Management of low grade glioma s: update on recent trials

Management of low grade glioma s: update on recent trials Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

Agustin Avilés 1, Serafin Delgado 2, Alejandra Talavera 3, Natividad Neri 3, Judith Huerta-Guzmán 3

Agustin Avilés 1, Serafin Delgado 2, Alejandra Talavera 3, Natividad Neri 3, Judith Huerta-Guzmán 3 Eur J Haematol 2002: 68: 144 149 Printed in UK. All rights reserved Copyright # Blackwell Munksgaard 2002 EUROPEAN JOURNAL OF HAEMATOLOGY ISSN 0902-4441 Combined therapy in advanced stages (III and IV)

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Lymphoma Diagnosis and Classification

Lymphoma Diagnosis and Classification Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

Sonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995

Sonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995 Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Overview: 1. Epidemiology of childhood cancer survivorship 2. Late effects 3. Palliative care of survivors 4. Examples

Overview: 1. Epidemiology of childhood cancer survivorship 2. Late effects 3. Palliative care of survivors 4. Examples Childhood Cancer Survivorship Jacqueline Casillas, M.D., M.S.H.S. Associate Program Director of the UCLA-LIVESTRONG LIVESTRONGTM TM Center of Excellence for Survivorship Care Overview: 1. Epidemiology

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University

More information

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s National Cancer Institute

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory

More information

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN + IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

The Treatment of Leukemia

The Treatment of Leukemia The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome

More information

Leukaemia and lymphoma what s the difference?

Leukaemia and lymphoma what s the difference? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk Leukaemia and lymphoma what s the difference? This is a difficult question to answer simply but it is one that is often

More information

Lymphoma. Measurability of Quality Performance Indicators Version 2.0

Lymphoma. Measurability of Quality Performance Indicators Version 2.0 Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September

More information

Oncology Best Practice Documentation

Oncology Best Practice Documentation Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings

More information

Non-Hodgkin s Lymphoma

Non-Hodgkin s Lymphoma Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant

More information

Many people with non-hodgkin lymphoma have found an educational support group helpful. Support

Many people with non-hodgkin lymphoma have found an educational support group helpful. Support Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

CARDIOVASCULAR PROBLEMS IN SURVIVORS OF CHILDHOOD CANCER AND THEIR SIBLINGS

CARDIOVASCULAR PROBLEMS IN SURVIVORS OF CHILDHOOD CANCER AND THEIR SIBLINGS Swiss Childhood Cancer Registry (SCCR) CARDIOVASCULAR PROBLEMS IN SURVIVORS OF CHILDHOOD CANCER AND THEIR SIBLINGS Julien Caccia, Corina S. Rueegg, Eva-Maria Hau, Nicolas X. von der Weid, Gisela Michel,

More information

New Hampshire Childhood Cancer

New Hampshire Childhood Cancer Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children

More information

A Career in Pediatric Hematology-Oncology? Think About It...

A Career in Pediatric Hematology-Oncology? Think About It... A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

More information

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006 Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Cycle frequency: Every four weeks Total number of cycles: 6-8

Cycle frequency: Every four weeks Total number of cycles: 6-8 Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and

More information

Lymphoma Diagnostics, Standard of Care Treatment Options and Rescue Options

Lymphoma Diagnostics, Standard of Care Treatment Options and Rescue Options Lymphoma Diagnostics, Standard of Care Treatment Options and Rescue Options Kelvin Kow, DVM, DACVIM (Medical Oncology) University of Florida College of Veterinary Medicine Lymphoma is the most common malignancy

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

Lymphoma: The Roleof Nurses in the Treatment Process

Lymphoma: The Roleof Nurses in the Treatment Process Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &

More information

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

Medical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA

Medical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA THE UNIVERSITY OF BRITISH COLUMBIA Department of Urologic Sciences Faculty of Medicine Gordon & Leslie Diamond Health Care Centre Level 6, 2775 Laurel Street Vancouver, BC, Canada V5Z 1M9 Tel: (604) 875-4301

More information

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular

More information

Non-Hodgkin Lymphoma Richard Orlowski, MD

Non-Hodgkin Lymphoma Richard Orlowski, MD Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,

More information

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black

More information

STEM CELL TRANSPLANTS

STEM CELL TRANSPLANTS UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the

More information

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data (Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too

More information

Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)

Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS) Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical

More information

Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide

Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood

More information

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior

In ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior - First and only immunostimulatory antibody approved in the European Union for multiple myeloma - Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti

More information

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.

CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc. Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

J Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael

More information

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

Histopathologic results

Histopathologic results Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric

More information

FAQ About Prostate Cancer Treatment and SpaceOAR System

FAQ About Prostate Cancer Treatment and SpaceOAR System FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop

More information

Lymphoma. Starting Point. Diagnosed with Lymphoma?

Lymphoma. Starting Point. Diagnosed with Lymphoma? ESSENTIALS Lymphoma Diagnosed with Lymphoma? It s important to understand everything you can about your diagnosis, treatment options, and places to go for support. This will help you make treatment decisions

More information

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200

Disease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200 GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung

More information

Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,

More information

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015

Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Chemobrain Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Terminology Chemotherapy-associated cognitive dysfunction Post-chemotherapy cognitive impairment Cancer treatment-associated cognitive

More information

Canine Lymphoma Frequently Asked Questions by Pet Owners

Canine Lymphoma Frequently Asked Questions by Pet Owners Canine Lymphoma Frequently Asked Questions by Pet Owners What is lymphoma? The term lymphoma describes a diverse group of cancers in dogs that are derived from white blood cells called lymphocytes. Lymphocytes

More information

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 Doxorubicin/Cisplatin Osteosarcoma - neoadjuvant Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 (3 before surgery) Ensure adequate renal function Pre & post-hydration,

More information

False positive PET in lymphoma

False positive PET in lymphoma False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

Before, Frank's immune cells could

Before, Frank's immune cells could Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years

More information

PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION

PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION This booklet was designed to help you and the important people in your life understand the treatment of high dose chemotherapy with stem cell support: a procedure

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal

CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:

More information